Imunon, Inc. (NASDAQ:IMNN)
| Market Cap | 4.62M-79.4% |
| Revenue (ttm) | 0 |
| Net Income | -14.72M+6.5% |
| EPS | -4.53+66.6% |
| Shares Out | 4.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,069.72 |
| Open | 1.15 |
| Previous Close | 1.14 |
| Day's Range | 1.04 - 1.18 |
| 52-Week Range | 1.05 - 5.39 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | 10.00(+809.09%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IMNN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMNN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMNN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMNN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IMNN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMNN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IMNN
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $76.56K |
Estimated from each fund’s disclosed top holdings × AUM
IMNN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IMNN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score